Medical device company Cerus Endovascular has developed 021 Contour Neurovascular System for the treatment of saccular intracranial aneurysms.

The device is compatible with smaller commercially available 021 microcatheters and was developed to provide a combination of flow diversion and flow disruption through a single device implant.

It is a fine mesh braid that targets the neck of the aneurysm away from the vulnerable dome. In addition, the device is designed to be self-anchored for stability, re-sheathable for precise placement.

The new, lower profile system will enable physicians to access more distally challenging vascular anatomies.

Cerus Endovascular president Dr Stephen Griffin said: “In response to numerous requests from the clinical community and physicians we work closely with, we continue to aggressively expand our product portfolio to offer an even more comprehensive suite of products to meet market needs, complementing our Contour 027 device and Neqstent platform, which recently received CE Mark approval.”

The company’s CE-Marked Neqstent Coil Assisted Flow Diverter device was designed for the treatment of a range of aneurysm morphologies, including wide-necked bifurcation and bifurcation aneurysms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Cerus Endovascular chairman Dr Sam Milstein said: “This latest approval testifies to the strength of our product pipeline and represents another critical step in our go-to-market strategy via a controlled roll-out.

“We look forward to initiating sales later this year and are pleased to be able to offer the medical community additional, key solutions that will meaningfully benefit patient care.”

Earlier this year, the company raised $19m in a Series B financing from institutional investors to implement its go-to-market strategy and expand product portfolio.